Research Article

Endobronchial management of malignant central airway obstruction: the first 6-year single center experience

Volume: 5 Number: 5 September 4, 2019
EN

Endobronchial management of malignant central airway obstruction: the first 6-year single center experience

Abstract

Objectives: Central airway obstruction (CAO) develops in 20-30% of lung malignancies during the disease. The symptoms related to obstruction often result in poor quality of life and poor prognosis. Interventional bronchoscopic treatments are now recommended in guidelines to improve quality of life and symptom palliation in this patient group. In our study, we aimed to determine the efficacy and safety of our methods in the malignant CAO caused by endobronchial exophytic tumors.

Methods: Between May 2012 and August 2018, 432 endobronchial debulking procedures were performed in 388 patients with symptomatic malignant CAO due to endobronchial exophytic or mixed lesions.

Results: Primary lung tumors were the most common cause of airway stenosis (84.0%). The most common debulking technique was argon plasma coagulation assisted mechanical debridement (APC+MD) (79.9%). Airway patency was achieved with additional stents (10.2%) in the operations. The success rate of airway patency was 85.5% in APC+MD method, 75.6% in cryorecanalisation method, 91.7% in electrocautery assisted MD method, 100% in MD method and overall success rate was 85.4%. Stent use rate was significantly higher in the stenosis around main carina (42.9%) than in other localizations (p < 0.001). The overall serious complication rate was 2.1%. Procedure-related dead rate was 0.2%.

Conclusions: Endobronchial treatment of malignant CAO with interventional bronchoscopic procedures is effective and safe. The first 6 years of experience in our interventional pulmonary clinic show that it has similar characteristics with the world experience in the endobronchial treatment of malignant CAO. 

Keywords

References

  1. [1] Ginsberg RJ, Vokes EE, Ruben A. Non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th Edn. Philadelphia: Lippincott-Raven, 1997:858-911.
  2. [2] Laumanen R, Watson W. Autopsy findings. In: Watson W, ed. Lung Cancer: a Study of Five Thousand Memorial Hospital Cases. St Louis: Mosby, 1968;504-10.
  3. [3] Hollingsworth HM. Wheezing and stridor. Clin Chest Med 1987;8:231-40.
  4. [4] Macha HN, Becker KO, Kemmer HP. Pattern of failure and survival in endobronchial laser resection. A matched pair study. Chest 1994;105:1668-72.
  5. [5] Walser EM, Robinson B, Raza SA, Ozkan OS, Ustuner E, Zwischenberger J. Clinical outcomes with airway stents for proximal versus distal malignant tracheobronchial obstructions. J Vasc Interv Radiol 2004;15:471-7.
  6. [6] Nihei K, Ishikura S, Kawashima M, Ogino T, Ito Y, Ikeda H. Short-course palliative radiotherapy for airway stenosis in non-small cell lung cancer. Int J Clin Oncol 2002;7:284-8.
  7. [7] Simoff MJ, Lally B, Slade MG, Goldberg WG, Lee P, Michaud GC, et al. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e455S-e497S.
  8. [8] Herth FJ, Eberhardt R, Becker HD, Ernst A. Relief of malignant airway obstruction: a prospective and randomised comparison of five different endoscopic techniques. Chest 2005;128:209S.

Details

Primary Language

English

Subjects

Respiratory Diseases

Journal Section

Research Article

Publication Date

September 4, 2019

Submission Date

April 20, 2019

Acceptance Date

June 18, 2019

Published in Issue

Year 2019 Volume: 5 Number: 5

APA
Aktaş, Z., Yılmaz, A., Öztürk, A., Güllü, Y. T., & Karataş, M. (2019). Endobronchial management of malignant central airway obstruction: the first 6-year single center experience. The European Research Journal, 5(5), 879-885. https://doi.org/10.18621/eurj.556443
AMA
1.Aktaş Z, Yılmaz A, Öztürk A, Güllü YT, Karataş M. Endobronchial management of malignant central airway obstruction: the first 6-year single center experience. Eur Res J. 2019;5(5):879-885. doi:10.18621/eurj.556443
Chicago
Aktaş, Zafer, Aydın Yılmaz, Ayperi Öztürk, Yusuf Taha Güllü, and Mevlüt Karataş. 2019. “Endobronchial Management of Malignant Central Airway Obstruction: The First 6-Year Single Center Experience”. The European Research Journal 5 (5): 879-85. https://doi.org/10.18621/eurj.556443.
EndNote
Aktaş Z, Yılmaz A, Öztürk A, Güllü YT, Karataş M (September 1, 2019) Endobronchial management of malignant central airway obstruction: the first 6-year single center experience. The European Research Journal 5 5 879–885.
IEEE
[1]Z. Aktaş, A. Yılmaz, A. Öztürk, Y. T. Güllü, and M. Karataş, “Endobronchial management of malignant central airway obstruction: the first 6-year single center experience”, Eur Res J, vol. 5, no. 5, pp. 879–885, Sept. 2019, doi: 10.18621/eurj.556443.
ISNAD
Aktaş, Zafer - Yılmaz, Aydın - Öztürk, Ayperi - Güllü, Yusuf Taha - Karataş, Mevlüt. “Endobronchial Management of Malignant Central Airway Obstruction: The First 6-Year Single Center Experience”. The European Research Journal 5/5 (September 1, 2019): 879-885. https://doi.org/10.18621/eurj.556443.
JAMA
1.Aktaş Z, Yılmaz A, Öztürk A, Güllü YT, Karataş M. Endobronchial management of malignant central airway obstruction: the first 6-year single center experience. Eur Res J. 2019;5:879–885.
MLA
Aktaş, Zafer, et al. “Endobronchial Management of Malignant Central Airway Obstruction: The First 6-Year Single Center Experience”. The European Research Journal, vol. 5, no. 5, Sept. 2019, pp. 879-85, doi:10.18621/eurj.556443.
Vancouver
1.Zafer Aktaş, Aydın Yılmaz, Ayperi Öztürk, Yusuf Taha Güllü, Mevlüt Karataş. Endobronchial management of malignant central airway obstruction: the first 6-year single center experience. Eur Res J. 2019 Sep. 1;5(5):879-85. doi:10.18621/eurj.556443

Cited By